Navigation Links
Novadaq to hold fiscal 2007 year-end and fourth quarter results conference call and webcast
Date:3/18/2008

TORONTO, March 18 /PRNewswire-FirstCall/ - Novadaq(R) Technologies Inc. (TSX: NDQ), a developer of real-time medical imaging systems and image guided therapies for the operating room, will host a conference call and live webcast on Tuesday, March 25, 2008 at 4:30 p.m. E.T. to discuss the financial results for the fourth quarter and full year ended December 31, 2007.

To access the conference call by telephone, dial 416-644-3417 or 1-800-732-6179. Please connect approximately ten minutes prior to the beginning of the call to ensure participation. The conference call will be archived for replay until April 1, 2008 at midnight. To access the archived conference call, dial 416-640-1917 or 1-877-289-8525 and enter the reservation number 21266249 followed by the number sign.

A live audio webcast of the conference call will be available at http://www.novadaq.com. Please connect at least ten minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived at the above website for 365 days.

About Novadaq Technologies

Novadaq Technologies Inc. (TSX: NDQ) develops and commercializes medical imaging systems and real-time image guided therapies for use in the operating room. Novadaq's proprietary ICG imaging systems can be used to visualize blood vessels, nerves and the lymphatic system during a variety of surgical procedures. Novadaq's SPY(R) Imaging System, commercially available worldwide, enables cardiac surgeons to visually assess coronary vasculature and bypass graft functionality during the course of heart bypass surgery. The SPY System is expandable to include upgrade kits for use during other surgeries such as other cardiovascular, plastic, reconstructive and organ transplant surgery allowing surgeons to evaluate blood flow and tissue and organ perfusion. In addition, SPY is ideal for use during
'/>"/>

SOURCE Novadaq Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Novadaq to present at Cowen Healthcare Conference
2. NOVADAQs SPY System to be Featured During Live Broadcast of Robotic Surgery
3. Novadaq Data Presented at 2008 Society of Thoracic Surgeons Meeting
4. Novadaqs SPY System receives clearance for use in organ transplant surgery
5. Novadaqs SPY Imaging System named Product of the Year by Frost and Sullivan
6. Novadaq to present at BMO Healthcare Conference
7. Novadaq to present at Piper Jaffray Healthcare Conference
8. Novadaq announces third quarter 2007 conference call and webcast
9. Novadaq launches PINPOINT: Companys first minimally invasive imaging system
10. Novadaq Resumes Normal Business Operations by Securing ICG for SPY
11. The Quantum Group Announces 1st Quarter Financial Results for Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:DecisionView Launches StudyOptimizer(TM) 4 2DecisionView Launches StudyOptimizer(TM) 4 3The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 4659 1Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 4659 2Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 4659 3Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 4659 4Natural born divers and the molecular traces of evolution 9035 1Natural born divers and the molecular traces of evolution 9035 2Reading the brain without poking it 9033 1Reading the brain without poking it 9033 2Reading the brain without poking it 9033 3Reading the brain without poking it 9033 4Reading the brain without poking it 9033 5